BiotechTube
Meacor

Meacor

Cambridge, United States· Est.
meacor.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $23.5M

Overview

Meacor is an early-stage cardiovascular device innovator targeting the large unmet need in mitral and tricuspid valve regurgitation. The company's core technology is the CryoCinch system, which utilizes a proprietary cryoadhesion technique for anchor placement in a beating heart to perform a transcatheter annuloplasty. With a strong academic foundation from McGill University and experienced leadership, Meacor is positioned to advance a potentially disruptive platform for structural heart disease, though it remains pre-revenue with its device in the investigational stage.

Cardiovascular

Technology Platform

Proprietary cryoadhesion anchoring platform for transcatheter valve repair. Features an on-demand cryo-adhesive steerable catheter tip for stable attachment to moving heart tissue, enabling placement of interconnected anchors that are cinched to perform annuloplasty.

Funding History

2
Total raised:$23.5M
Series A$20M
Seed$3.5M

Opportunities

The large and growing untreated patient population with mitral and tricuspid regurgitation, especially elderly patients with comorbidities who are ineligible for surgery, represents a multi-billion dollar market.
The platform's potential to replicate the surgical gold standard of annuloplasty via a minimally invasive approach could address a significant unmet need and capture market share from both surgery and existing transcatheter leaflet repair devices.

Risk Factors

Major risks include the technical and clinical failure of the novel cryoadhesion technology in human trials, intense competition from large, well-funded medical device companies, and the significant regulatory hurdles and capital required to achieve FDA approval and commercial launch for a Class III device.

Competitive Landscape

Meacor operates in the highly competitive transcatheter mitral and tricuspid intervention space, competing against large players like Abbott (MitraClip, TriClip), Edwards Lifesciences (PASCAL), Medtronic, and Boston Scientific, as well as other annuloplasty-focused startups. Differentiation hinges on proving CryoCinch's unique cryo-anchoring offers superior safety, ease of use, or durability compared to existing leaflet repair or other annuloplasty systems.

More companies in United States →